BioStreamline Project Outcomes

CPI have reported successful outcomes the £11.2 million BioStreamline project – a collaborative project involving six partners across the UK including Lonza Biologics, UCB Celltech, Sphere Fluidics, Horizon Discovery, Alcyomics Ltd and CPI.

The BioStreamline project focused on accelerating monoclonal antibody production and overcoming bottlenecks in biologics manufacturing, with an aim to optimise the discovery and development of cost-effective next generation biotherapeutics.

Key outcomes include:

  • the development of Cyto-Mine® microfluidic picodroplet technology and workflows
  • the expression and purification of more than 50 monoclonal antibodies (mAbs) that have contributed to the design of a developability tool
  • the addition of seven job opportunities at CPI that lead into career pathways in molecular biology


Reflecting on these outcomes, our Vice President of Sales and Marketing, Dr Rob Marchmont stated:

​“We are delighted at the outcomes of the BioStreamline project. The development of the Cyto-Mine® platform provides the crucial acceleration needed in monoclonal antibody development and production. Deploying Cyto-Mine® in the biologics area significantly improves efficiencies and reduces timelines in the development workflow and therefore will boost the entry of biologics into the supply chain. Overall this has the potential to have a huge impact on the way biotherapeutics are produced in the UK.”

Dr Rob Marchmont, Vice President of Sales and Marketing, Sphere Fluidics


Visit CPI to read more:

Sphere Fluidics introduces Cyto-Cellect Human IgGK Detection Kit

Sphere logo


Sphere Fluidics introduces Cyto-Cellect Human IgGK Detection Kit


  • First in a new range to advance identification and selection of cells with the highest productivity

  • Assay-ready reagent kit to reduce timelines and enhance efficiency in cell line development

Cambridge, UK, 9 September 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, today introduced the Cyto-Cellect™ Human IgGK Detection Kit, to be used in conjunction with the Cyto-Mine® Single Cell Analysis System for rapid and cost-effective measurement of antibody class and productivity in cell line development.

The Cyto-Cellect Human IgGK Detection Kit has been developed to provide Cyto-Mine users with an easy-to-use, standardized assay format for the detection of secreted human antibodies in picodroplets. The sensitive FRET-based assay rapidly detects the presence of human IgG with kappa light chain after secretion from encapsulated cells, to characterize and measure antibody production. Rapid detection of IgG enables high-throughput identification and selection of cells with the highest productivity for more efficient cell line development.

With optimized ratios of Sphere Fluidics’ Human IgGK Detection probes, the Cyto-Cellect Human IgGK Detection Kit offers a sensitive and robust assay ideal for streamlining cell isolation and titer determination. The complete kit has been manufactured without the use of animal-derived materials, offering an animal-origin-free reagent kit that provides confidence in the reproducibility and consistency of the assay and conforms to regulatory requirements in cell line development.

Dr Zoe Nilsson, Global Product Marketing Manager, Sphere Fluidics, said: “Our expert team has applied extensive knowledge of assay requirements to develop the Cyto-Cellect Human IgGK Detection Kit, offering users a sensitive, yet robust assay solution for the Cyto-Mine platform. The addition of this assay-ready kit to Sphere Fluidics’ product portfolio provides a rapid, yet cost-effective solution to further support and reduce cell line development timelines.”

The Cyto-Mine platform will be on display in Boston, MA at BioProcess International from 9–12 September 2019 (Stand #1306).

For more information about Sphere Fluidics’ Cyto-Cellect Human IgGK Detection Kit, please visitκ-detection-kit